Evidence map›Paper›PMID 37644744›Full record

ArticleCurrent radiopharmaceuticals2024

An Investigation of the Relationship Between

Ozan Kandemir, Fadime Demir

Abstract read
PubMed Publisher
In one paragraph

Article in Current radiopharmaceuticals, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Advances in lymphatic metastasis of non-small cell lung cancer.Cell communication and signaling : CCS · 2024
    Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Ozan KandemirDepartment of Nuclear Medicine, Faculty of Medicine, Sıtkı Kocman University, Mugla, Turkey.ORCID 0000-0003-3978-1222
Fadime DemirNuclear Medicine Department, Kayseri City Health Application and Research Center, Health Sciences University, Kayseri, Turkey.ORCID 0000-0002-9799-6398
Kayseri Eğitim ve Araştırma Hastanesi · TRMuğla University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMediastinal lymph node metastasis is an important prognostic factor in non-small cell lung cancer (NSCLC) patients without distant metastases.

objectiveThis study aims to investigate whether maximum standardized uptake (SUVmax), mean standardized uptake (SUVmean), metabolic tumor volume (MTV), and tumor lesion glycolysis (TLG) values of the primary tumor measured by

methodsThis retrospective study included eighty NSCLC patients who underwent preoperative Positron Emission Tomography/Computed Tomography (PET/CT) for diagnosis and staging. The patients were stage I-III and had no distant metastases. Tumor metabolic parameters such as SUVmax, SUVmean, MTV, and TLG at PET/CT imaging were measured for preoperative diagnosis and staging, and the postoperative pathology results of the patients were examined. The pathology results divided patients with and without lymph node metastasis into two groups. The groups were compared with the student's t-test and chi-square test regarding

resultsFifteen (18.8%) patients were female, and 65 (81.3%) were male. According to the postoperative pathology results, while 30 (37.5%) patients had lymph node metastasis, 50 (62.5%) did not. There was a significant difference between the groups regarding tumor SUVmax and SUVmean values (p = 0.036, p = 0.045). Overall survival in the N0 group was significantly higher than in the N1 + N2 group (p = 0.034); median survival was 30.2 months in N0 cases and 27.3 months in N1 and N2 groups.

conclusionSUVmax and SUVmean values are significantly higher in patients with lymph node metastases than in patients without lymph node metastases, and this finding may provide useful information for predicting lymph node metastasis in patients with resectable NSCLC.

Indexed as

Carcinoma, Non-Small-Cell LungFluorodeoxyglucose F18Lung NeoplasmsLymphatic MetastasisNeoplasm StagingPositron Emission Tomography Computed TomographyRadiopharmaceuticalsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesFluorodeoxyglucose F18Radiopharmaceuticals18F-2-fluoro-2-deoxy-D-glucoselymph node metastasismaximum standardized uptake valuemean standardized uptake.Non-small cell lung cancerpositron emission tomography

Identifiers

PMID37644744
OpenAlexW4386271865

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.